MIRM stock forecast, quote, news & analysis
Mirum Pharmaceuticals Inc... Show more
Mirum Pharmaceuticals (MIRM) Stock Analysis: Pipeline Catalysts Meet Insider Selling Pressure
Key Takeaways
- Mirum Pharmaceuticals shares pulled back approximately 7.7% over the trailing 30 days, retreating from near-52-week-high levels around $124 to $114 amid insider selling activity.
- The company reported Q1 2026 revenue of $159.9 million, a 43% year-over-year increase, and raised full-year product sales guidance to $660–$680 million.
- Multiple late-stage pipeline catalysts are approaching, including an FDA PDUFA date of September 26, 2026, for zilurgisertib in fibrodysplasia ossificans progressiva (FOP).
- Analyst consensus remains broadly bullish with a Moderate Buy rating and an average price target of $143.40, implying significant upside from current levels.
- Insider sales executed under Rule 10b5-1 plans by the CEO, CFO, and other executives have drawn investor attention, though they represent pre-scheduled transactions.
Current Market Snapshot
Mirum Pharmaceuticals (NASDAQ: MIRM) has experienced a period of consolidation over the past month, with shares declining from approximately $124 in late June to around $114 as of late July 2026. The stock touched a 52-week high of $130 earlier in the quarter before giving back some gains. The pullback comes despite a broadly favorable analyst backdrop and multiple positive clinical developments, suggesting that profit-taking and insider selling activity have weighed on near-term sentiment. With a market capitalization near $6.9 billion and a 200-day moving average around $100, the stock remains well above longer-term technical levels.
Mirum Pharmaceuticals (MIRM) Business Overview and Competitive Position
Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare liver and genetic diseases. The company markets three FDA-approved products: LIVMARLI (maralixibat) for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). LIVMARLI remains the primary growth engine, generating $113.8 million in Q1 2026 net product sales, up 55% year-over-year. Mirum's commercial infrastructure and established relationships with hepatologists and rare disease specialists create a durable competitive advantage that is difficult for new entrants to replicate.
Recent Developments Driving MIRM
Several significant events have shaped investor sentiment around Mirum in recent weeks. The company and partner Incyte (INCY) presented positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in FOP at the ENDO 2026 conference in mid-June, reinforcing confidence ahead of the September 26 PDUFA date. If approved, zilurgisertib would represent Mirum's fourth commercial product and could generate peak sales exceeding $200 million. Additionally, volixibat met its primary endpoint in the VISTAS Phase 2b study for primary sclerosing cholangitis (PSC), and brelovitug showed positive Phase 2b data in chronic hepatitis delta virus (HDV), with Phase 3 top-line results expected in the second half of 2026.
On the sentiment side, multiple executives — including CEO Christopher Peetz, CFO Eric Bjerkholt, and SVP Jolanda Howe — sold shares in early July under pre-arranged Rule 10b5-1 trading plans. While such plans are established in advance and not indicative of executives' views on current valuation, the combined insider selling of over 65,000 shares during the quarter has garnered attention. Meanwhile, Wall Street analysts have remained constructive: JPMorgan raised its target to $125 with an Overweight rating, RBC lifted its target to $148, and Citigroup (C) initiated coverage with a Buy rating and a $145 target.
Trending AI Robots
For traders seeking a data-driven edge in stocks like Mirum Pharmaceuticals, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron hosts hundreds of algorithmic trading bots that monitor thousands of tickers across multiple strategies, timeframes, and performance metrics. Only the top-performing and most relevant bots are featured in the Trending section, helping users quickly identify strategies with demonstrated momentum. Whether focused on swing trading, trend following, or pattern recognition, these bots provide actionable signals grounded in technical and fundamental analysis. Exploring the Trending AI Robots page can help investors discover quantitative approaches that complement their own research.
2026 Outlook and What Investors Should Watch
The second half of 2026 stands out as a potentially transformative period for Mirum. The most immediate catalyst is the FDA's September 26 PDUFA decision on zilurgisertib for FOP — a binary event that could unlock a new revenue stream and validate the company's rare genetic disease strategy. Beyond that, investors should monitor topline data from the brelovitug Phase 3 AZURE-1 and AZURE-4 studies in HDV expected later in the year, as well as the planned volixibat NDA submission for PSC. The EXPAND Phase 3 study of LIVMARLI in additional rare cholestatic conditions, with data expected in Q4 2026, could further expand the drug's label. On the financial side, Mirum expects to reach operating cash flow positivity in 2027 and GAAP profitability around 2028, making expense management and commercial execution key variables to track. Potential risks include regulatory setbacks, slower-than-expected product launches, pricing pressure, and the inherent binary nature of biotech clinical readouts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MIRM in upward trend: price may jump up because it broke its lower Bollinger Band on July 31, 2026
MIRM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where MIRM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRM advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 284 cases where MIRM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MIRM moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIRM as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MIRM turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
MIRM moved below its 50-day moving average on July 31, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MIRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.667) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (9.804) is also within normal values, averaging (420.906).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company. which focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
Industry Biotechnology